These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

773 related items for PubMed ID: 27334259

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN, Hanna C, Giovane R.
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants.
    van Willigen M, Vonk AM, Yeoh HY, Kruisselbrink E, Kleizen B, van der Ent CK, Egmond MR, de Jonge HR, Braakman I, Beekman JM, van der Sluijs P.
    Life Sci Alliance; 2019 Feb; 2(1):. PubMed ID: 30659068
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
    Boj SF, Vonk AM, Statia M, Su J, Vries RR, Beekman JM, Clevers H.
    J Vis Exp; 2017 Feb 11; (120):. PubMed ID: 28287550
    [Abstract] [Full Text] [Related]

  • 36. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK, Azad MA, Han ML, Tony Zhou Q, Wang J, Huang JX, Cooper MA, Doi Y, Baker MA, Bergen PJ, Muller MT, Li J, Velkov T.
    ACS Infect Dis; 2016 Jul 08; 2(7):478-88. PubMed ID: 27626100
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK, Reyes-Ortega F, Li J, Velkov T.
    Clin Pharmacol Ther; 2017 Jan 08; 101(1):130-141. PubMed ID: 27804127
    [Abstract] [Full Text] [Related]

  • 39. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
    Van Goor F, Yu H, Burton B, Hoffman BJ.
    J Cyst Fibros; 2014 Jan 08; 13(1):29-36. PubMed ID: 23891399
    [Abstract] [Full Text] [Related]

  • 40. Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
    Uliyakina I, Botelho HM, da Paula AC, Afonso S, Lobo MJ, Felício V, Farinha CM, Amaral MD.
    Int J Mol Sci; 2020 Jun 25; 21(12):. PubMed ID: 32630527
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.